Ponatinib

Generic Name
Ponatinib
Brand Names
Iclusig
Drug Type
Small Molecule
Chemical Formula
C29H27F3N6O
CAS Number
943319-70-8
Unique Ingredient Identifier
4340891KFS
Background

Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.

Indication

1.用于治疗达沙替尼或尼洛替尼治疗无效的慢性期、进展期或急性期的慢性粒细胞白血病（CML）；或不能耐受达沙替尼或尼洛替尼者，以及临床不适合用伊马替尼进行后续治疗的患者；或T315I突变者。

2.用于治疗达沙替尼治疗无效的费城染色体阳性急性淋巴细胞白血病（Ph+ALL）；或不能耐受达沙替尼者，以及临床不适合用伊马替尼进行后续治疗的患者；或T315I突变者。

Associated Conditions
Accelerated Phase Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukaemias (ALL), Chronic Phase Chronic Myeloid Leukemia, Blast phase Chronic myeloid leukemia
Associated Therapies
-
Clinical Trials
Related News

The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

First Posted Date
2020-10-19
Last Posted Date
2023-10-03
Lead Sponsor
Fondazione per la Medicina Personalizzata
Target Recruit Count
400
Registration Number
NCT04591431
Locations
🇮🇹

I.R.S.T. Srl Irccs, Meldola, Italy

🇮🇹

Ospedale Classificato Sacro Cuore - Don Calabria, Negrar, Italy

🇮🇹

I.R.C.C.S. Istituto Oncologico Veneto, Padova, Italy

and more 34 locations

A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

First Posted Date
2020-08-06
Last Posted Date
2024-08-09
Lead Sponsor
Takeda
Target Recruit Count
11
Registration Number
NCT04501614
Locations
🇺🇸

Children's Hospital Los Angeles, Los Angeles, California, United States

🇺🇸

Ann and Robert H Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States

🇺🇸

Nationwide Children's Hospital, Columbus, Ohio, United States

and more 61 locations

Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse

First Posted Date
2020-07-17
Last Posted Date
2024-10-22
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Target Recruit Count
67
Registration Number
NCT04475731
Locations
🇮🇹

Aou Ospedali Riuniti "Umberto I - G.M. Lancisi - G. Salesi"- Ancona - Sod Clinica Ematologica, Ancona, Italy

🇮🇹

Area Vasta N. 5 Ascoli Piceno - S. Benedetto Del Tronto, Presidio Ospedaliero Av5 Osp. Gen. Prov.Le "C.G.Mazzoni" - Uoc Ematologia, Ascoli Piceno, Italy

🇮🇹

Ao Di Rilievo Nazionale E Di Alta Specialità "San Giuseppe Moscati" - Avellino - Uoc Ematologia Con Unità Di Trapianto, Avellino, Italy

and more 19 locations

The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation

Phase 2
Active, not recruiting
Conditions
Chronic Myeloid Leukemia
Acute Lymphoblastic Leukemia
Interventions
Drug: Ponatinib
First Posted Date
2020-01-18
Last Posted Date
2023-11-01
Lead Sponsor
Otsuka Beijing Research Institute
Target Recruit Count
90
Registration Number
NCT04233346
Locations
🇨🇳

Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China

🇨🇳

Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

🇨🇳

Xiangya Hospital Central South University, Changsha, Hunan, China

and more 11 locations

Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia

First Posted Date
2019-12-05
Last Posted Date
2024-11-25
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
30
Registration Number
NCT04188405
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase

First Posted Date
2019-08-28
Last Posted Date
2024-04-08
Lead Sponsor
Centre Leon Berard
Target Recruit Count
170
Registration Number
NCT04070443
Locations
🇫🇷

CHU Limoges - Hôpital Dupuytren, Limoges, France

🇫🇷

Centre Hospitalier Annecy-Genevois, Annecy, France

🇫🇷

Iuct Toulouse - Oncopole, Toulouse, France

and more 25 locations

Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia

Phase 2
Conditions
Chronic Myeloid Leukemia
Interventions
Drug: Ponatinib
First Posted Date
2019-08-02
Last Posted Date
2019-08-02
Lead Sponsor
Fundación Teófilo Hernando, Spain
Target Recruit Count
40
Registration Number
NCT04043676
Locations
🇪🇸

Hospital Trials i Pujol, Badalona, Barcelona, Spain

🇪🇸

Hospital Vall D'Hebron, Barcelona, Spain

🇪🇸

Hospital Regional de Malaga, Málaga, Spain

and more 6 locations

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

First Posted Date
2019-05-01
Last Posted Date
2024-12-10
Lead Sponsor
Incyte Biosciences International Sàrl
Target Recruit Count
60
Registration Number
NCT03934372
Locations
🇮🇹

Aou Policlinico S. Orsola-Malpighi Bologna, Bologna, Italy

🇮🇹

Asst Degli Spedali Civili Di Brescia, Brescia, Italy

🇮🇹

A.O.U Citta Della Salute E Della Scienza Di Torino Presidio Ospedaliero Infantile Regina Margherita, Torino, Italy

and more 29 locations

PONAZA : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS

First Posted Date
2019-03-29
Last Posted Date
2020-08-07
Lead Sponsor
Versailles Hospital
Target Recruit Count
40
Registration Number
NCT03895671
Locations
🇫🇷

Institut Bergonie, Bordeaux, France

🇫🇷

Centre Hospitalier Universitaire de Nantes, Nantes, France

🇫🇷

Centre Henri Becquerel, Rouen, France

and more 26 locations

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1
Terminated
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Anatomic Stage IV Breast Cancer AJCC v8
Anemia
Ann Arbor Stage III Hodgkin Lymphoma
Ann Arbor Stage III Non-Hodgkin Lymphoma
Ann Arbor Stage IV Hodgkin Lymphoma
Ann Arbor Stage IV Non-Hodgkin Lymphoma
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Castration-Resistant Prostate Carcinoma
Interventions
Drug: Abemaciclib
Drug: Abiraterone
Drug: Afatinib
Biological: Bevacizumab
Drug: Bicalutamide
Procedure: Biospecimen Collection
Drug: Bortezomib
Drug: Cabazitaxel
Drug: Cabozantinib
Drug: Capecitabine
Drug: Carboplatin
Drug: Celecoxib
Drug: Cobimetinib
Drug: Copanlisib
Drug: Dabrafenib
Drug: Dacomitinib
Drug: Darolutamide
Drug: Dasatinib
Drug: Doxorubicin
Biological: Durvalumab
Drug: Enasidenib
Drug: Entrectinib
Drug: Enzalutamide
Drug: Erlotinib
Drug: Everolimus
Drug: Fluorouracil
Drug: Idelalisib
Drug: Imatinib
Biological: Ipilimumab
Drug: Lenvatinib
Drug: Leucovorin
Drug: Lorlatinib
Drug: Losartan
Drug: Nab-paclitaxel
Drug: Neratinib
Biological: Nivolumab
Drug: Olaparib
Drug: Oxaliplatin
Drug: Palbociclib
Drug: Panobinostat
Biological: Pembrolizumab
Biological: Pertuzumab
Drug: Ponatinib
Other: Quality-of-Life Assessment
Drug: Regorafenib
Drug: Ruxolitinib
Drug: Sirolimus
Drug: Sorafenib
Drug: Sunitinib
Drug: Trametinib
Biological: Trastuzumab Emtansine
Drug: Tretinoin
Drug: Vemurafenib
Drug: Venetoclax
Drug: Vismodegib
Drug: Vorinostat
First Posted Date
2019-03-18
Last Posted Date
2024-03-04
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
2
Registration Number
NCT03878524
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy